Dr. Osman's Care Philosophy

"Understanding the whole surgical patient who deserves to be cared for with dignity, encouragement and grace".

Clinical Focus

  • Cardiothoracic Surgery
  • Ventricular Assist Devices
  • Thoracic Surgery
  • Vascular surgery
  • Minimal Invasive Surgery
  • VATS
  • Valve repair

Academic Appointments

Administrative Appointments

  • President, Heliopolis Rotaract Club; Cairo, Egypt, (Rotary Youth Division) (1994 - 1995)
  • Chief Fellow, Department of Cardiothoracic Surgery, Boston University Medical Center Hospital, Boston, MA (1997 - 1998)
  • Chief Resident, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA (2003 - 2004)
  • Chief Resident, Department of Cardiovascular & Thoracic Surgery, Allegheny General Hospital, Pittsburgh, PA (2005 - 2006)
  • Member of Continuing Medical Education Committee, Sharon Regional Health System (2007 - 2009)
  • Member Board of Directors, American Heart Association; Mercer Division (2007 - 2009)
  • Medical Record Committee Member, Sharon Regional Health System (2008 - 2009)
  • Lung Cancer Update; “Where Do we Stand?”, Saint Agnes Medical Center, Fresno, CA (2010 - 2010)
  • Cancer Committee, Saint Agnes Medical Center, Fresno, CA (2010 - Present)
  • Minimal Invasive OR Committee, Saint Agnes Medical Center, Fresno, CA (2010 - Present)
  • Multi disciplinary Thoracic Tumor Board Committee, Saint Agnes Medical Center, Fresno, CA (2010 - Present)
  • Planning Chair; Annual Oncology Symposium, Saint Agnes Medical Center, Fresno, CA (2010 - 2010)
  • Infectious disease Committee, Saint Agnes Medical Center, Fresno, CA (2010 - Present)
  • Planning Committee for the Oncology Symposium, Saint Agnes Medical Center, Fresno, CA (2011 - 2011)

Honors & Awards

  • Scholarship for the "Master's Degree" (M.Sc.) of General Surgery, Cairo University, Cairo, Egypt (1993 - 1994)
  • Rotary International Scholar - Rotary Foundation : "Ambassadorial Scholarship", Dept of Surgery, Div of Thoracic & CV Surgery, Univ of Cincinnati, College of Medicine (1994 - 1995)

Professional Education

  • Medical Education:Faculty of Medicine Cairo University (1991) Egypt
  • Residency:Drexel University College of MedicinePA
  • Internship:Drexel University College of MedicinePA
  • Residency:Allegheny General HospitalPA
  • Board Certification: Thoracic Surgery, American Board of Thoracic Surgery (2008)
  • Board Certification: General Surgery, American Board of Surgery (2006)
  • Residency, Allegheny General Hospital, Pittsburgh, PA, Cardiothoracic Surgery (2006)
  • Residency, Drexel University College of Medicine, Philadelphia, PA, General Surgery (2004)
  • Fellowship, Boston University Medical Center, Boston, MA, Cardiothoracic Surgery (1998)
  • Fellowship, The Cleveland Clinic Foundation, Cleveland, OH, Cardiothoracic Surgery (1996)
  • MSc, Cairo University, Cairo, Egypt, General Surgery (1995)
  • MD, Cairo University, Cairo, Egypt, Medicine and Surgery (1989)

Research & Scholarship

Current Research and Scholarly Interests

- Heart failure surgery with a special emphasis on Ventricular Assisted Devices (VAD).
- High risk valve surgery.
- Heart Transplant Immunology.
- Minimal Invasive Techniques.
- Video Assisted Thorascopic Surgery (VATS).


All Publications

  • Desensitization of Highly HLA-Sensitized Heart Transplant Candidates Using High-Dose Intravenous Immunoglobulin and Rituximab with Successful Transplantation J. Am. Coll. Cardiol. Czer L.C., Osman A., et al. 2010; 55 (A19): E179
  • Chapter 50: Use meticulous attention to correct positioning when placing a patient in the lateral decubitus position Avoiding Common Surgical Errors Osman, A. 2006: 111-3
  • Chapter 91: Do not prescribe Viagra to a patient taking nitrates and vice versa Avoiding Common Surgical Errors Osman, A. 2006: 212-3
  • Effect of rosiglitaxone on restenosis after coronary stenting in patients with type 2 diabetes AMERICAN HEART JOURNAL Osman, A., Otero, J., Brizolara, A., Waxman, S., Stouffer, G., Fitzgerald, P., Uretsky, B. F. 2004; 147 (5)


    Thiazolidinediones have been shown to have an antiproliferative vascular effect in experimental models. We sought to study the effect of rosiglitazone on in-stent restenosis in patients with established type 2 diabetes.Patients with treated type 2 diabetes (mean duration 5.5 +/- 7.5 years) referred for coronary stenting were randomized in a double-blind fashion to receive oral rosiglitazone or placebo for 6 months. Quantitative coronary angiography and intravascular ultrasound data were obtained at baseline and follow-up. Plasma plasminogen activator inhibitor-1 levels were prospectively measured.Sixteen patients were enrolled. There were no significant differences in follow-up in-stent luminal diameter stenosis measured by quantitative coronary angiography or in-stent luminal area stenosis and neointimal volume index obtained by intravascular ultrasound, nor were there any differences in plasma plasminogen activator inhibitor-1 levels after long-term use despite improvement in diabetes control and insulin sensitivity.Rosiglitazone, given at the time of stent implantation in treated diabetics, did not reduce in-stent restenosis in this small series. The vascular biological effects of this agent await further clarification in humans and evaluation in larger clinical trials.

    View details for DOI 10.1016/j.ahj.2003.12.006

    View details for Web of Science ID 000221479100018

    View details for PubMedID 15131558

  • A Rapidly Expanding Inflammatory Aneurysm of The Abdominal Aorta The 23rd Annual Scientific Meeting Osman, A., et al. 2001
  • Accelerated allograft degeneration after aortic valve endocarditis ANNALS OF THORACIC SURGERY Osman, A., McCann, J., Shemin, R. J., Lazar, H. L. 1999; 68 (5): 1849-1850


    Early calcification of aortic allografts is usually seen in children less than 3 years of age. We describe a case of a 22-year-old intravenous drug user who developed calcific aortic valve stenosis less than 3 years after an allograft root replacement for endocarditis.

    View details for Web of Science ID 000083887900062

    View details for PubMedID 10585075

  • Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits ANNALS OF THORACIC SURGERY Aldea, G. S., O'Gara, P., Shapira, O. M., Treanor, P., Osman, A., Patalis, E., Arkin, C., Diamond, R., Babikian, V., Lazar, H. L., Shemin, R. J. 1998; 65 (2): 425-433


    We have demonstrated that the use of heparin-bonded cardiopulmonary bypass circuits (HBCs) combined with a lower anticoagulation protocol as an adjunct to an integrated blood conservation strategy decreases the incidence and magnitude of homologous transfusion and improves clinical outcome in patients undergoing primary coronary artery bypass grafting. It is not known whether it is the lower anticoagulation protocol that influences outcome in patients treated with HBCs. Furthermore, the thrombogenic risk of using lower anticoagulation with HBCs still is debated.To answer these questions, a prospective randomized study was conducted in which 244 patients undergoing primary coronary artery bypass grafting were treated with HBCs and randomized to undergo either a full (activated clotting time, > 450 seconds) or a lower (activated clotting time, > 250 seconds) anticoagulation protocol. In addition to clinical outcome, levels of thrombin generation markers during and after cardiopulmonary bypass were assessed in a consecutive subset of 58 patients (full anticoagulation profile = 28, lower anticoagulation profile = 30) by measuring thrombin-antithrombin complexes and prothrombin fragment 1.2. Levels of these markers also were correlated with the activated clotting time during cardiopulmonary bypass.Preoperative and intraoperative risk profiles and other characteristics were similar in both groups, with more than 60% of patients undergoing nonelective operation. Compared with the full anticoagulation protocol group, patients in the lower anticoagulation protocol group were less likely to require blood products (24.2% versus 35.8%, respectively; p = 0.047) and received substantially fewer homologous donor units (0.50 +/- 0.92 versus 1.08 +/- 2.10 U, respectively; p = 0.005). Clinical outcomes were uniformly outstanding (but similar) in both treatment groups, with a modest reduction in the length of the hospital stay in the lower anticoagulation protocol group (5.26 +/- 1.23 versus 5.63 +/- 1.73 days, respectively; p = 0.05). The use of HBCs with a lower anticoagulation protocol was not associated with any adverse clinical events. Thrombin generation increased during cardiopulmonary bypass in both treatment groups, but was unrelated to the anticoagulation protocol or the activated clotting time (r2 = 0.03). No differences between the full and lower anticoagulation protocol groups were noted in the number of microemboli detected by transcranial Doppler analyses during cardiopulmonary bypass (n = 40) or in the postoperative neurologic and neuropsychologic outcomes (n = 30).This study definitively demonstrates that, when used appropriately, patients who are treated with HBCs and a lower anticoagulation protocol have a lower incidence and magnitude of homologous transfusion and are not at any added risk for clinical, hematologic (thrombin-antithrombin complex and fragment 1.2 measurements), or microscopic (transcranial Doppler analyses) thromboembolic complications or for neurologic or neuropsychologic deficits.

    View details for Web of Science ID 000072128100026

    View details for PubMedID 9485240

  • Heparin-bonded circuits improve clinical outcomes in emergency coronary artery bypass grafting JOURNAL OF CARDIAC SURGERY Aldea, G. S., Lilly, K., Gaudiani, J. M., O'Gara, P., Stein, D., Bao, Y. S., Treanor, P., Osman, A., Shapira, O. M., Lazar, H. L., Shemin, R. J. 1997; 12 (6): 389-397


    Compared to patients undergoing elective or urgent coronary artery bypass grafting (CABG), those undergoing emergency CABG (EM-CABG) have a higher morbidity and mortality. The use of heparin-bonded circuits (HBC) has been shown to improve clinical outcomes in nonemergent CABG patients. It is not known, however, whether the improved hemostasis and attenuation of the inflammatory response to cardiopulmonary bypass, conferred by HBC, can overcome the high incidence of comorbid risk factors in (EM-CABG) patients and improve their outcomes. A retrospective analysis of 206 consecutive patients undergoing EM-CABG over 4 years (1993-1997) at one institution was performed. Eighty-one patients were treated with conventional non-heparin-bonded circuits (NHBC) with full anticoagulation protocol (FAP, activated clotting time [ACT] > 480 sec); 125 patients were treated with HBC and a lower anticoagulation protocol (LAP, ACT > 280 seconds). Outcomes and results were collected prospectively and are presented as mean +/- SD. Preoperative risk profiles were similar in both treatment groups. Postoperatively, compared with the NHBC group, patients treated with HBC/LAP required fewer homologous donor units (4.1 +/- 10.7 vs 8.2 +/- 13.6 units, p = 0.005), were less likely to require inotropic support (18.6% vs 38.3%, p = 0.005), and had a lower incidence of perioperative myocardial infarction (MI, 3.2% vs 12.3%, p = 0.04) and pulmonary complications (4.0% vs 12.3%, p = 0.04). The use of HBC/LAP resulted in a decreased incidence of postoperative complications (12.8% vs 28.4%, p = 0.01, odds ratio 0.37 with 95% confidence interval [CI] 0.18-0.76). This resulted in a shorter duration of ventilatory support (30.5 +/- 54.0 vs 72.8 +/- 16.7 hours, p = 0.009), ICU stay (38.2 +/- 36.5 vs 91.5 +/- 68.7 hours, p = 0.009), hospital stay (8.0 +/- 7.1 vs 11.0 +/- 8.9 days, p = 0.008), and therefore cost. In conclusion, the use of HBC/LAP in EM-CABG resulted in a reduction of homologous transfusion and postoperative complications associated with decreased hospital stays and cost.

    View details for Web of Science ID 000074862000006

    View details for PubMedID 9690498

  • Results of Thoracotomy Approach For Reoperative Myocardial Revascularization The Cleveland Clinic's Experience Osman, A. 1996
  • Recent Advances In Conduits Used In Coronary Artery Bypass Grafting submitted for partial fulfillment of the Master Degree (M.Sc.) in General Surgery Osman, A. 1994
  • Five Ambassadors Of Goodwill Building Up A Bridge Of Friendship Rotary Magazine Osman, A. 1991: 8-10